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Abstract. Autophagy is a lysosomal degradation 
mechanism that is essential for cell survival, differentiation, 
development, and homeostasis. Autophagy protects cells 
from various stresses, including protecting normal cells 
from harmful metabolic conditions, and cancer cells from 
chemotherapeutics. In the current study, a cytarabine 
arabinoside (Ara-C)-sensitive U937 leukemia cell line and 
an Ara-C-resistant U937 (U937/AR) cell line were assessed 
for baseline autophagy activity by investigating the LC3-I 
conversion to LC3-II, performing EGFP-LC3 puncta, 
an acidic autophagolysosome assay, and measuring the 
expression of various autophagy-related genes. The results 
demonstrated significantly higher autophagic activity in the 
U937/AR cells compared with the U937 cells, when the cells 
were cultured with or without serum. Furthermore, an increase 
in the autophagic activity in starved U937/AR cells was 
demonstrated, compared with that in the starved U937 cells. 
Administration of an autophagy inhibitor demonstrated no 
change in cell death in the two cell lines when cultured with 
serum, however, it induced cell death regardless of the Ara-C 
sensitivity when the cell lines were cultured without serum. 
In addition, the U937 cells demonstrated an Ara-C resistance 
when cultured without serum. Co-treatment with Ara-C and 
the autophagy inhibitor significantly induced cell death in 
the U937/AR and Ara-C-sensitive U937 cells. In conclusion, 
autophagy serves an important role in protecting U937 cells 
from Ara-C and in the development of Ara-C resistance. 
Inhibition of autophagy combined with the Ara-C treatment 
in the U937 cells augmented the anti-leukemic effect of Ara-C 
and overcame Ara-C resistance, suggesting that autophagy 
may be an important therapeutic target to further improve the 
treatment outcome in patients with acute myeloid leukemia.
Introduction
Autophagy refers to any lysosomal degradation pathway and 
is essential for survival, differentiation, development and 
homeostasis (1). During autophagy, an autophagosome, a 
double-membraned vesicle sequestering cytoplasmic materials, 
and a lysosome, fuse together to form an autolysosome (2). The 
two principal physiological roles of autophagy are to maintain 
synthesis of macromolecules and ATP, and to eliminate defective 
or abnormal proteins and organelles. These functions allow 
cells to survive various metabolic stresses, such as nutritional 
and growth factor depletion, or hypoxia, and be protected from 
infection, neurodegenerative diseases, genomic instabilities 
or tumor initiation (3). Various pathological conditions are 
associated with defects in autophagy, as it serves an important 
role in homeostasis (1). Autophagy has been considered a 
tumor suppressor pathway (4-6) following the establishment 
of an association between autophagy and cancer in 1999, when 
the autophagy‑related gene (ATG) beclin‑1 was identified as 
a candidate tumor suppressor (7). Numerous genetic links 
have been identified between defects in autophagy and cancer. 
Tumor suppressor genes involved in the upstream inhibition 
of mammalian target of rapamycin (mTOR) signaling, 
including phosphatase and tensin homolog (4), tuberous 
sclerosis 1, and tuberous sclerosis 2 (5), stimulated autophagy. 
By contrast, TOR-activating oncogene products, such as 
Ras, phosphoinositide 3-kinase (PI3K) and protein kinase B 
(Akt), inhibit autophagy (6). Furthermore, a previous study 
hypothesized that chemoradiotherapy induces the accumulation 
of autophagosomes in various cancer cell lines and eliminates 
cancer cells by induction of caspase-independent autophagic 
and caspase-dependent cell death (8). However, autophagy 
may promote survival of cancer cells during chemotherapy 
and serve a role in chemoresistance (9). Therefore, inhibiting 
autophagy by targeting certain autophagy-related (ATG) genes 
may accelerate, rather than prevent cell death (10).
Previous studies in the field of hematology have primarily 
focused on elucidating the role of autophagy in chronic myeloid, 
chronic lymphoid and acute promyelocytic leukemias, and 
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autophagy was associated with resistance to tyrosine kinase 
inhibitors, histone deacetylase inhibitors and hypomethylating 
agents (11-14). However, to the best of our knowledge, no 
previous study has investigated the possible association 
between autophagy and chemoresistance to cytosine 
arabinoside (1-β-d-arabinofuranosylcytosine; Ara-C) in acute 
myeloid leukemia (AML). Ara-C is a nucleoside analog used 
to induce complete remission or for post-remission therapy in 
AML (15). Ara-C acts as an anti-metabolite and induces cell 
death by competing with pyrimidine for incorporation into 
replicative DNA, which inhibits DNA polymerase activity and 
leads to chain elongation termination. Due to the important 
role of Ara-C in AML treatment, acquired resistance to Ara-C 
is one of the multiple factors leading to AML persistence or 
relapse. Therefore, novel therapeutic strategies are required 
to overcome the Ara-C resistance in myeloid leukemia 
cells, which is hypothesized to develop through various 
mechanisms. In the present study, the role of autophagy in 
myeloid leukemic cell lines was assessed according to Ara-C 
sensitivity, and whether inhibiting autophagy would overcome 
Ara-C resistance was investigated.
Materials and methods
Reagents and antibodies. Ara-C was purchased from 
Sigma-Aldrich (St. Louis, MO, USA), and was dissolved 
in distilled water and stored as a 100 mM stock solution. 
Hydroxychloroquine (HCQ) was purchased from Myung In 
Pharmaceutical Company, Ltd. (Seoul, South Korea) 
and dissolved in dimethyl sulfoxide (Sigma-Aldrich). 
Bafilomycin A1 (Ba‑A1) was purchased from Sigma-Aldrich. 
Fetal bovine serum (FBS) and Gibco RPMI 1640 medium 
containing 50 U/ml and 50 µg/ml streptomycin were purchased 
from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Rabbit 
polyclonal antibodies against human microtubule-associated 
protein 1 light chain 3 (LC3; cat. no. NB100-2220; 
dilution, 1:1,000), beclin-1 (cat. no. NB500-249; dilution, 
1:1,000), ATG9A (cat. no. NB110-56893; dilution, 1:1,000), 
ATG7 (NB110-74811) and mouse anti-human p62 (cat. 
no. H0008878; dilution, 1:1,000) were purchased from 
Novus Biologicals LLC (Littleton, CO, USA). Horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit (cat. no. 7074; 
dilution, 1:3,000) and horse anti-mouse (cat. no. 7072; 
dilution, 1:3,000) IgG secondary antibodies were obtained 
from Cell Signaling Technology, Inc. (Danvers, MA, USA). 
The Annexin V‑fluorescein isothiocyanate (FITC) apoptosis 
detection kit was purchased from BD Pharmingen (San Diego, 
CA, USA). All other chemicals were from Sigma-Aldrich. The 
GFP-LC3 plasmid was kindly provided by Dr Kim (Division 
of Pulmonology, Yonsei University College of Medicine, 
Seoul, South Korea).
Cell culture. The human leukemia cell line, U937, was obtained 
from the American Type Culture Collection (Rockville, MD, 
USA). The Ara-C-resistant U937 (U937/AR) cell line was 
established in our laboratory by exposing parental U937 cells 
to stepwise increasing concentrations of Ara-C (1 nM - 2 mM, 
usually at intervals of 10 passages) in complete RPMI 1640 
medium supplemented with 10% heat-inactivated FBS and 
100 U/ml penicillin. Resistant sublines were grown for longer 
than 6 months. To maintain exponential growth, cells were 
seeded at 1x105 cells/ml and passaged every 3 days.
Cell death assay. U937 and U937/AR cells were cultured on 
12-well plates (Corning Incorporated, Corning, NY, USA) at 
2x105 cells/well in medium containing RPMI 1640, 10% FBS 
and 100 U/ml penicillin and streptomycin for 24, 48 and 72 h. 
Cultured cells were washed with phosphate-buffered saline 
(PBS; Gibco; Thermo Fisher Scientific, Inc.) and incubated in 
100 µl 1X binding buffer containing 5 µl Annexin V-FITC, 
and the nuclei were counterstained with 10 µl propidium iodide 
according the kit manufacturer's instructions. The percentage 
of apoptotic cells was determined using a FACSCalibur flow 
cytometer and analyzed using CellQuest version 3.3 software 
(BD Immunocytometry Systems, San Jose, CA, USA).
Western blot analysis. U937 and U937/AR cells were 
cultured in 12-well plates at 2x105 cells/well in RPMI 1640 
medium with or without 10% FBS for 48 h. Cells were 
lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 
120 mM NaCl, 20 mM NaF, 1 mM EDTA, 5 mM ethylene 
glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid, 
15 mM sodium pyrophosphate, 1 mM benzamidine, 0.1 mM 
phenylmethylsulfonyl fluoride, and 1% Nonidet P-40, and 
this was briefly sonicated. The mitochondrial and cytosolic 
fractions were obtained using the QIA88 ProteoExtract 
Cytosolic/Mitochondria Fractionation kit (Oncogene 
Research Products, La Jolla, CA, USA). Protein yields were 
quantified using a detergent-compatible protein assay kit 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) according 
to the manufacturer's instructions. Equivalent amounts of 
protein (10 mg) were boiled for 10 min and separated by 
SDS-PAGE (15% for LC3; 12% for beclin-1 and p62; and 
10% for ATG9A and ATG7). Proteins were subsequently 
transferred to nitrocellulose membranes (GE Healthcare 
Bio-Sciences, Pittsburgh, PA, USA). Following blocking with 
0.05% Tris-buffered saline with Tween 20 (TBST) and 5% 
bovine serum albumin solution, or 5% skim milk, for 1 h at 
room temperature, blots were incubated with LC3, beclin-1, 
ATG9A, ATG7 and p62 primary antibodies overnight at 
4˚C. Blots were washed four times for 5 min with TBST and 
incubated for 1 h at room temperature with HRP-conjugated 
anti-rabbit or anti-mouse IgG secondary antibodies (1:3,000). 
Subsequent to washing with TBST, the reactive proteins were 
visualized using the enhanced chemiluminescence reagent 
(Amersham; GE Healthcare Life Sciences). The density of the 
protein bands on the membrane were scanned and analyzed 
with ImageJ (imagej.nih.gov/ij/).
EGFP‑LC3 puncta assay. U937 and U937/AR cell 
suspensions (2x106 cells) were immediately electroporated 
with pEGFP-LC3 cDNA using the Nucleofector™ 2b system 
(program T-20; Lonza Cologne GmbH, Cologne, Germany) 
according to the manufacturer's instructions. Immediately 
following electroporation, cells were resuspended in complete 
medium and incubated at 37˚C in a humidified 5% CO2 
incubator. pEGFP vector transfection was performed as control. 
After 24 h, cells were rinsed and resuspended in serum-free 
medium and incubated at 37˚C for 48 h. Cultured cells were 
centrifuged at 800 x g onto glass slides. Fluorescence images 
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were analyzed using an LSM 700 laser-scanning confocal 
microscope (Zeiss GmbH, Jena, Germany). The GFP-LC3 
puncta in a single cell were manually counted using confocal 
microscopy. For each group, 50 cells were randomly selected 
to estimate the average number of GFP-LC3 puncta per 
cell. Data presented are one representative experiment of a 
minimum of three independent repeats.
Transmission electron microscopy (TEM). For TEM evaluation, 
U937 and U937/AR cells were seeded in 12-well plates at 2x105 
cells/well and cultured with or without FBS for 48 h at 37˚C. 
Following incubation, the cells were collected and fixed for 
2 h at 4˚C with ice-cold 2% glutaraldehyde-paraformaldehyde 
(EMD Millipore, Billerica, MA, USA) and post‑fixed at 4˚C 
with 1% OsO4 (KeyGen Biotech Co. Ltd.; dissolved in 0.1 M 
PBS) for 2 h and dehydrated through serial dilutions of ethanol 
(50, 70, 90 and 100% for 15 min and then three times at 
100%) and infiltrated with propylene oxide (Sigma‑Aldrich) 
prior to embedding in epoxy resin using a Poly/Bed 812 kit 
(Polysciences, Inc., Warrington, PA, USA) at 65˚C electron 
microscope oven (TD-700; Dosaka EM, Kyoto, Japan) 
for 24 h. The embedded sections were cut into sections of 
250-250 nm for staining with toluidine blue (Sigma-Aldrich) 
and observation under a light microscope and into ultrathin 
sections (70 nm) were double-stained with 7% uranyl acetate 
for 20 min and lead citrate (Thermo Fisher Scientific, Inc.) for 
10 min for contrast staining. The sections were cut with an 
ultramicrotome (Leica EM UC7; Leica Microsystems GmbH, 
Wetzlar, Germany) and mounted on copper and nickel grids. 
Sections were viewed using a JEM-1011 system (JEOL USA, 
Inc., Peabody, MA, USA) at an acceleration voltage of 80 kV 
(Camera Megaview, Soft Imaging System, Berlin, Germany). 
Photoshop (Adobe Systems, Inc., San Jose, CA, USA) was 
used to further quantify the TEM images.
Statistical analysis. The statistical analysis was performed 
using the two-tailed Student's t-test. Unless otherwise 
indicated, data are expressed as the mean ± standard deviation. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Sensitivity of U937 and U937/AR leukemia cell lines to Ara‑C. 
The relative sensitivity of U937 and U937/AR to Ara-C was 
assessed in vitro as a baseline study. Following treatment with 
logarithmically scaled concentrations of Ara-C (100-103 µM), 
cell death was assessed using an Annexin V binding assay, 
combined with flow cytometry. As demonstrated in Fig. 1A, cell 
death was induced in a time-dependent manner in the Ara-C 
U937 cells. Ara-C (101 µM) induced cell death in 65.0±1.0 and 
81.7±0.8% of U937 cells after 48 and 72 h, respectively. The 
U937/AR cells were resistant to Ara-C and the maximum level 
of cell apoptosis observed was 16.6±0.2% at 72 h after treatment 
with the highest concentration of Ara-C (Fig. 1B).
Status of autophagy in U937 and U937/AR cells according to the 
culture conditions. Following standard cell culture conditions 
(media supplemented with FBS) and serum starvation, the 
status of autophagy was assessed. Western blot analysis results 
demonstrated that the LC3-II/I ratio in the U937/AR cells was 
significantly higher compared with that of the Ara‑C sensitive 
U937 cells, under the standard culturing condition with FBS 
(0.39±0.08 vs. 0.09±0.01; P=0.0389; Fig. 2A) and under serum 
starvation (1.21±0.08 vs. 0.30±0.04; P=0.0048; Fig. 2A). The 
fractional increases in the LC3-II/I ratio under serum starvation 
were ~3-fold in the two cell lines and thus, were not observed to 
be significantly different (P>0.05).
LC3 expression was assessed using the GFP-LC3 puncta 
assay. The results demonstrated a significant increase in the 
number of GFP-LC3 puncta per cell in the U937/AR cells 
compared with the U937 cells, regardless of culturing conditions 
(4.0±2.0 vs. 1.5±0.5 puncta per cell with FBS; P=0.0239 or 
29.5±2.5 vs. 12.2±1.2 puncta per cell without FBS; P<0.001; 
Fig. 2B). Furthermore, the total number of autophagosomes 
per cell was counted using TEM (Fig. 2C), and the results were 
similar to those from western blot and GFP-LC3 puncta assays. 
As demonstrated in Fig. 2C, the number of autophagosomes 
significantly increased when cells were cultured without FBS. 
The number of autophagosomes in U937/AR cells cultured 
without FBS was significantly higher than that in the U937 cells 
(19.3±3.5 vs. 8.7±1.5; P<0.05; Fig. 2C).
In addition, the expression of several autophagy-associated 
genes was determined. As demonstrated in Fig. 2D, the 
increase in beclin-1, ATG9A, ATG7 and p62/SQSTM1 protein 
expression levels was more prominent in the U937/AR cells 
(ratio to α-tubulin, 4.3, 2.6 and 3.7, respectively) compared with 
the U937 cells (ratio to α-tubulin, 1.3, 2.3 and 2.0, respectively) 
when cultured without FBS.
Effect of autophagy inhibitors in U937 and U937/AR cells 
cultured without serum. Following cell treatment with or 
without serum, the mechanism of action of the autophagy 
inhibitors affecting apoptosis was investigated. The U937 and 
U937/AR cells were treated with two autophagy inhibitors 
separately, Ba-A1 (2 nM) and HCQ (20 µg/ml) for 48 h. Untreated 
cell lines grow when cultured with FBS, but autophagic activity 
is required to prolong cell survival when cultured without FBS. 
As demonstrated in Fig. 3, the autophagy inhibitors induced cell 
death in <25% of the cells cultured with serum. In the cultures 
with FBS, the autophagy inhibitors increased cell death in the 
U937/AR cells compared with the U937 cells as follows: Ba-A1, 
6.2±0.5 vs. 1.6±0.4% (P<0.05); HCQ, 23.0±3.0 vs. 11.7±1.6% 
(P<0.05). These results were consistent with the status of 
autophagy in the U937 and U937/AR cells treated with FBS 
(Fig. 2).
Furthermore, in a comparison of FBS-cultured and serum 
starved cells, the autophagy inhibitors induced cell death in a 
significantly higher percentage of serum starved cells, compared 
with the FBS-treated cells as follows: Ba-A1, 62.9±2.7 vs. 
1.6±0.4% in U937 (P<0.05) and 88.7±0.9 vs. 6.2±0.5% in 
U937/AR (P<0.05); HCQ, 27.0±3.9 vs. 11.7±1.6% in U937 
(P<0.05) and 80.8±5.0 vs. 23.0±3.0% in U937/AR (P<0.05). 
In addition, the difference in cell death between U937 and 
U937/AR induced by the autophagy inhibitors was consistent 
and unaffected by culture conditions or the type of autophagy 
inhibitor used.
Induction of Ara‑C resistance by culture condition, and 
overcoming Ara‑C resistance by co‑treatment with Ara‑C and 
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autophagy inhibitors. The association of autophagic activity 
and Ara-C resistance was investigated. As demonstrated 
in Fig. 4, U937/AR cells were Ara-C resistant in all culture 
conditions. However, Ara-C treatment induced cell death in 
the U937 cell line with FBS. The Ara-C-sensitive U937 cells 
acquired Ara-C resistance upon culturing without FBS (Fig. 4; 
cell death rate, 70.9±3.8% with FBS vs. 11.9±3.0% without 
FBS; P<0.001).
Cell death was then assessed in the U937 and U937/AR 
cell lines following culturing without FBS and co-treatment 
with Ara-C and Ba-A1. To evaluate whether the co-treatment 
had an additive or synergistic effect on inducing cell death, 
a lower concentration of Ba-A1 (1 nM) was used to induce 
moderate cell death. Resistance to Ara-C in Ara-C-sensitive 
U937 cells was demonstrated upon serum starved culture 
and co-treatment with Ba-A1 and Ara-C (cell death rate, 
14.8±2.5% for Ara-C monotherapy vs. 60.5±3.2% for Ara-C 
and Ba-A1; P<0.01; Fig. 5A). Furthermore, the acquired Ara-C 
resistance was of higher significance in the U937/AR cells (cell 
death rate, 4.5±0.8% for Ara-C monotherapy vs. 59.2±1.2% for 
Ara-C and Ba-A1; P<0.001; Fig. 5B).
Discussion
Autophagy is a catabolic process that recycles intracellular 
components and selectively eliminates organelles for 
regulation and maintenance of quality control (1). The first 
step of autophagy is the formation of an isolation membrane 
and phagophore, the expansion of the membrane. The edges 
of the phagophore fuse to form an autophagosome, which 
further fuses with a lysosome to make an autolysosome, 
while the inner membrane and materials are degraded (2). 
Physiologically, autophagy defends against various forms of 
metabolic stress, including nutrient deprivation, growth factor 
depletion and hypoxia. Autophagic degradation generates free 
amino acids and fatty acids used by the tricarboxylic acid 
cycle to maintain cellular ATP production (3). Autophagy 
performs cellular functions to eliminate defective proteins or 
organelles, prevent abnormal protein aggregate accumulation 
and remove intracellular pathogens. In addition, previous 
studies demonstrated that autophagy may act as a guardian 
of the genome to limit DNA damage and chromosomal 
instability (16-18). This role may be associated with the 
preventive effects of autophagy against the initiation and 
progression of cancer. By contrast, defective autophagy has 
been proposed as a contributor to various human diseases. 
For example, patients with neurodegenerative diseases, such 
as Alzheimer's disease, Parkinson's and Huntington's diseases, 
have abnormal accumulation of autophagosomes in the 
brain (19,20), and germline or somatic mutations in genes, 
such as dynactin subunit p150 glued or ceroid-lipofuscinosis 
neuronal 3, have been associated with neurologic diseases (21). 
In addition, the liver, muscles and heart may be damaged by 
defective autophagy, and several inherited diseases, such as 
Danon or Pompe diseases, demonstrate the role of defective 
autophagy in their pathogenesis (22-24).
Abnormalities in the autophagic process may present 
in cancer. Liang et al (7) demonstrated that the ATG gene, 
beclin-1, was a candidate tumor suppressor gene in 1999, 
and previous studies have indicated that defective autophagy 
is closely associated with the initiation or progression of 
cancer (25-27). Certain mutations in genes affecting autophagy, 
such as beclin-1, Akt, PI3K, p53 and Bcl-2, serve a role in the 
pathogenesis of malignant lymphoma and breast, ovarian and 
prostate cancer (1).
Autophagy protects against cell starvation and hypoxia, 
which are the hallmarks of the tumor microenvironment. A 
previous study suggested that autophagy serves an important 
role in the chemoresistance of cancer to therapeutics that 
typically induce apoptosis (9). Numerous clinical trials 
evaluating autophagy in various solid cancers, including 
breast (28), lung (29), melanoma (30), rectal/colon (31), renal 
cell carcinoma (32), prostate (33) and pancreatic cancer (34), 
have demonstrated inconsistent results regarding the anticancer 
effect of autophagy manipulation (35). Certain previous 
studies demonstrated that autophagic cell death observed 
during chemotherapy acted as an anticancer machinery (8,36), 
however other studies suggested that autophagy prevents 
apoptosis of cancer cells from chemotherapy (9,37). These 
inconsistent results may be due to the dynamic nature of 
autophagy and the diversity of molecules or organelles 
targeted by it. Autophagy may target tumor-initiating proteins 
developed in normal cells, therefore suppressing tumor 
activity. In addition, cancer cells may preserve themselves 
using autophagy during chemotherapy, thus promoting cancer 
cell survival.
The myeloid leukemias are a heterogeneous group of diseases 
characterized by neoplastic cells that infiltrate the blood, bone 
marrow and other tissues of the hematopoietic system. In 
previous studies, induction of autophagy was demonstrated to 
Figure 1. Induction of cell death by treating leukemia cell lines with Ara-C. (A) Ara-C-sensitive U937 cells demonstrated time-dependent induction of cell 
death. (B) U937/AR cells were highly resistant to Ara-C. Ara-C, cytarabine arabinoside; AR, Ara-C-resistant.
  A   B
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be important for the death of leukemic cells (11-14,38), and 
the induction of autophagy by various drugs, such as imatinib 
mesylate, arsenic trioxide, everolimus, brevinin-2R and 
eupalinin A, was attempted. Autophagy may be an important 
pathway of cell death during various chemotherapeutic 
modalities, and manipulation of autophagy may be a useful 
clinical application for targeting multidrug-resistant leukemia. 
Although triggering autophagy may be a potential therapeutic 
strategy to overcome drug resistance, inhibiting autophagy 
may be another therapeutic strategy to improve the outcome 
of anticancer treatments. For example, autophagy acts as a 
prosurvival mechanism and contributes to drug resistance 
in various types of leukemia (38). By contrast, inhibition of 
autophagy was documented to enhance the therapeutic benefit 
of tyrosine kinase inhibitors in Philadelphia (Ph)-positive 
leukemias, and the tumor anti-leukemic effect of the histone 
deacetylase inhibitor, SAHA, was augmented by co-treatment 
with an autophagy inhibitor (11). Overcoming drug resistance 
Figure 3. The effect of autophagy inhibitors on inducing cell death in 
U937 and U937/AR cells according to the culturing conditions. The effects 
of the autophagy inhibitors, Ba-A1 and HCQ, on inducing cell death were 
minimal following culturing with serum. However, in the U937 cells cultured 
without serum, treatment with the autophagy inhibitors induced cell death 
regardless of Ara-C resistance. AR, cytarabine arabinoside-resistant; Ba-A1, 
bafilomycin-A1; HCQ, hydrochloroquine.
Figure 2. The status of autophagy in U937 and U937/AR cells according to the culturing conditions. (A) Assay for conversion of LC3-I to LC3-II showed 
a significantly higher LC3‑II/LC3-I ratio in U937/AR cells compared to that in U937 cells cultured with or without serum. (B) The number of GFP-LC3 
puncta as assessed by the EGFP‑LC3 puncta assay. (C) The number of autophagosomes observed by transmission electron microscopy are significantly larger 
in the U937/AR cells compared to the U937 cells when cultured without serum. (D) Autophagy related genes are highly expressed in U937/AR cells when 
cultured without serum. AR, cytarabine arabinoside‑resistant; LC3, microtubule‑associated protein 1 light chain 3; GFP, green fluorescent protein; AVd, late 
autolysosomes; AVi, early autophagosomes; ATG9A, autophagy-related protein 9A.
  A   B
  C   D
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by manipulating autophagy was primarily attempted for 
Ph-positive types of leukemia, such as chronic myeloid 
leukemia, Ph-positive acute lymphoblastic leukemia and 
acute promyelocytic leukemia (39,40). However, the role of 
autophagy in association with drug resistance in AML remains 
unclear.
In the current study, the status of autophagy in AML 
cell lines was assessed according to the resistance against 
Ara-C, a chemotherapeutic agent used to induce remission. 
In addition, an attempt was made to overcome the Ara-C 
resistance by combination treatment with an autophagy 
inhibitor and Ara-C. As demonstrated in Fig. 2, specific 
characteristics of autophagy in the U937 and U937/AR cell 
lines were identified, including LC3‑I‑to‑LC3-II conversion 
(Fig. 2A), formation of EGFP-LC3 puncta (Fig. 2B) and 
acidic autophagolysosomes (Fig. 2C). The three assays 
demonstrated a consistent highly active autophagic status in 
the U937/AR cells compared with the U937 cells. To verify 
the autophagic activity at the molecular level, the expression 
of autophagy-associated molecules was investigated. 
Following autophagy initiation by the ATG1-ATG13 protein 
complex, which is activated by the absence of signaling of 
the nutrient-sensing kinase mTOR, class III PI3K-beclin-1 
complexes promote formation of the isolation membrane. 
Elongation of the isolation membrane is then mediated by two 
ubiquitin-like conjugation systems as follows: i) ATG7 and 
ATG10 act to conjugate ATG5 to ATG12; ii) the ATG5-ATG12 
conjugate acts with ATG7 and ATG3 to conjugate ATG8 to 
phosphatidylethanolamine in the membrane of the growing 
autophagosome (41). In addition, the expression of beclin-1, 
ATG9A, ATG7 and p62/SQSTM1 was determined. The 
autophagy-associated molecules were expressed in similar 
patterns as observed in the LC3-I-to-LC3-II conversion, 
EGFP-LC3 puncta and autophagosome assays. The results 
of the current study demonstrated that the U937/AR cells 
had higher levels of autophagic activity compared with the 
U937 cells, and that autophagic activity increased after 
Ara-C treatment, thus the ability of an autophagy inhibitor 
to overcome Ara-C resistance in the U937/AR cells and to 
improve the antileukemic effect of Ara-C in the U937 cells 
was assessed. As the Ara-C-resistant U937/AR cell line was 
established by exposing parental U937 cells to increasing 
concentrations of Ara-C in culture media with FBS, the 
increasing autophagic activity in U937/AR cells may be 
induced by Ara-C. Ara-C is an anti-metabolite and other 
anti‑metabolites, such as 5‑fluorouracil or 6‑thioguanine have 
been demonstrated to induce autophagy (42,43). The current 
study demonstrated that the U937/AR cells had a higher 
level of autophagic activity than U937 cells when the cells 
were treated with Ara-C (Fig. 2). The augmented autophagic 
activity in Ara-C-treated U937/AR cells may be one of 
the mechanisms leading to the U937/AR cells resistance 
to higher concentrations of Ara-C with longer treatment 
durations (Fig. 1B). The evidence of the anti-apoptotic role 
Figure 4. Induction of Ara-C resistance in U937 cells cultured without serum. Following culturing of Ara-C sensitive U937 cells without serum, the U937 cells 
gained Ara‑C resistance. The percentage of cell death by Ara‑C treatment alone was significantly decreased with serum starvation. Ara‑C, cytarabine arabi-
noside; AR, Ara‑C‑resistant; FITC, fluorescein isothiocyanate.
Figure 5. The effect of co-treatment with Ara-C and autophagy inhibitors on inducing cell death in U937 and U937/AR cells. (A) U937 cells and (B) U937/AR cells 
were co-treated with Ara-C and the autophagy inhibitor Ba-A1. Co-treated cells demonstrated a significantly higher percentage of cell death compared with 
the untreated or Ara-C-treated groups. Ara-C, cytarabine arabinoside; AR, Ara-C-resistant; Ba-A1, bafilomycin-A1.
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of autophagy in the U937 cells during metabolic stress was 
supported by the results demonstrated when U937 cells were 
cultured with autophagy inhibitors under starvation (Fig. 3). 
As U937 is a leukemia cell line, serum starvation alone cannot 
induce sufficient cell death, however, when the cell lines were 
cultured without FBS and treated with autophagy inhibitors, 
sufficient cell death was induced. Furthermore, culturing the 
cells without FBS may transform Ara-C sensitive U937 cells 
to Ara-C resistant U937 cells with no further manipulations 
(Fig. 4). Although the underlying mechanism of this effect was 
not fully investigated, the maintenance of autophagic activity 
may be associated with the acquisition of Ara-C resistance, 
even in the absence of Ara-C. Combination treatment with 
a low dose of the autophagy inhibitor and Ara-C improved 
the anti-leukemic activity in the U937 cells (Fig. 5A) and 
overcame Ara-C resistance in the U937/AR cells.
Previous studies have emphasized the role of autophagy in 
AML. One study demonstrated that overexpression of melanoma 
differentiation-associated gene-7/interleukin-24 inhibited 
autophagy and strongly augmented the anti-leukemia activity 
in an AML cell line and in a mouse model of leukemia (44). 
Another study demonstrated that bone-morphogenetic 
protein 4, a member of the TGF-β super-family, has a role 
in promoting chemoresistance through the activation of 
autophagy and subsequent inhibition of apoptosis in leukemic 
cells (45). S100A8, a member of the S100 calcium-binding 
protein family, has also been proposed to be involved in 
the development of chemoresistance in leukemic cells by 
regulating autophagy, and has been suggested as a novel target 
for improving leukemia therapy (12,46).
In conclusion, the role of autophagy as a protector against 
cellular stress may be important for the survival of AML 
cells when treated with chemotherapeutics. Chemoresistant 
AML cells demonstrated increased autophagic activity that 
augmented the anti-leukemic activity of Ara-C and overcame 
Ara-C resistance in vitro. Prior to validating the clinical benefit 
of autophagy inhibition, the genetic and epigenetic mechanisms 
of autophagy that protect leukemic cells and promote resistance 
to chemotherapeutics should be further investigated.
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